OSPEMIFENE - Generic Drug Details

What are the generic drug sources for ospemifene and what is the scope of freedom to operate?

Ospemifene is the generic ingredient in two branded drugs marketed by Hetero Labs Ltd V and Duchesnay, and is included in two NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ospemifene has fifty-three patent family members in twenty-one countries.

There are six drug master file entries for ospemifene. One supplier is listed for this compound.

Summary for OSPEMIFENE

International Patents:	53
US Patents:	2
Tradenames:	2
Applicants:	2
NDAs:	2
Drug Master File Entries:	6
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	59
Clinical Trials:	11
Patent Applications:	1,048
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OSPEMIFENE
What excipients (inactive ingredients) are in OSPEMIFENE?	OSPEMIFENE excipients list
DailyMed Link:	OSPEMIFENE at DailyMed

Recent Clinical Trials for OSPEMIFENE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tongji Hospital	EARLY_PHASE1
Hospital Clinic of Barcelona	Phase 4
Emory University	Phase 4

See all OSPEMIFENE clinical trials

Pharmacology for OSPEMIFENE

Drug Class	Estrogen Agonist/Antagonist
Mechanism of Action	Selective Estrogen Receptor Modulators

Anatomical Therapeutic Chemical (ATC) Classes for OSPEMIFENE

G03XC	Selective estrogen receptor modulators
G03X	OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

Paragraph IV (Patent) Challenges for OSPEMIFENE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OSPHENA	Tablets	ospemifene	60 mg	203505	1	2020-12-29

US Patents and Regulatory Information for OSPEMIFENE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hetero Labs Ltd V	OSPEMIFENE	ospemifene	TABLET;ORAL	215574-001	Feb 13, 2024		DISCN	No	No
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013		RX	Yes	Yes			Y
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013		RX	Yes	Yes

Expired US Patents for OSPEMIFENE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013

EU/EMA Drug Approvals for OSPEMIFENE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Shionogi B.V.	Senshio	ospemifene	EMEA/H/C/002780Senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women.	Authorised	no	no	no	2015-01-14

International Patents for OSPEMIFENE

Country	Patent Number	Title	Estimated Expiration
Cyprus	1111689
Lithuania	C1713458
Portugal	1718288
European Patent Office	1718288	FORMULATIONS SOLIDES D'OSPEMIFENE (SOLID FORMULATIONS OF OSPEMIFENE)
Japan	2007522190

Supplementary Protection Certificates for OSPEMIFENE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1713458	216 5010-2015	Slovakia		PRODUCT NAME: OSPEMIFEN; REGISTRATION NO/DATE: EU/1/14/978 20150119
1713458	CA 2015 00031	Denmark		PRODUCT NAME: OSPEMIFENE; REG. NO/DATE: EU/1/14/978/001-002 20150115
1713458	122015000048	Germany		PRODUCT NAME: OSPEMIFEN; REGISTRATION NO/DATE: EU/1/14/978/001-002 20150115
1713458	28/2015	Austria		PRODUCT NAME: OSPEMIFEN; REGISTRATION NO/DATE: EU/1/14/978/001-002 20150119
1713458	1590030-1	Sweden		PRODUCT NAME: OSPEMIFENE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/14/978/001 20150119

OSPEMIFENE Market Analysis and Financial Projection

Last updated: February 14, 2026

Market Dynamics and Financial Trajectory for Ospemifene

Ospemifene, marketed primarily as Osphena, is an estrogen receptor modulator used to treat dyspareunia associated with vulvar and vaginal atrophy stemming from menopause. Its market involves established competition, limited therapeutic indications, and evolving regulatory and patent landscapes.

---

Market Size and Growth Drivers

The global demand for ospemifene stems from an increasing menopausal female population and unmet needs in estrogen-related dyspareunia. The menopause prevalence is projected to reach 1.2 billion women worldwide by 2030, with a significant portion experiencing symptomatic vulvovaginal atrophy (VVA).

The global vaginal estrogen therapy market was valued at approximately USD 2.2 billion in 2021, expected to grow at a compound annual growth rate (CAGR) of 6-8% through 2028, partly driven by ospemifene's market segment.

Key Regions and Market Penetration

• North America: Dominates market share (estimated 50%) due to high awareness and insurance coverage.
• Europe: Second largest market, with growth driven by aging populations.
• Asia-Pacific: Rapidly expanding, driven by increased menopausal health awareness, but still limited market share compared to Western regions.

Competitive Landscape

Ospemifene's main competitor is hormone therapy (HRT), especially vaginal estrogen creams and tablets, which account for more than 70% of the market. Non-hormonal options include lubricants and moisturizers, with newer agents like prasterone gaining ground.

Key competitors include:

• Localized vaginal estrogen products (e.g., Estrace, Vagifem)
• Over-the-counter lubricants
• Alternative non-hormonal therapies (e.g., dehydroepiandrosterone (DHEA))

Ospemifene’s unique selling proposition is its non-estrogenic approach, reducing concerns about estrogen-related risks, such as breast cancer or thromboembolic events.

Regulatory Environment and Patent Status

Ospemifene received FDA approval in 2013. Patent protection in the U.S. extends until approximately 2028, with generic versions anticipated thereafter, potentially impacting revenue. In Europe and other territories, patent expirations vary, influencing regional pricing and market penetration.

Regulatory environments are evolving, emphasizing safety data and post-market surveillance, with some regions considering expanding indications.

Sales and Revenue Trajectory

In 2021, the drug generated USD 125 million globally, with expectations to reach USD 175 million by 2025 given increasing demand and expanding prescribing practices.

Key factors influencing revenues include:

• Patent expiry dates
• Adoption rate among healthcare providers
• Competitor product launches
• Reimbursement policies

R&D and Pipeline Developments

While ospemifene's current indication remains limited to dyspareunia, development efforts are exploring broader uses:

• Osteoporosis management
• Breast tissue modulation
• Sexual dysfunction enhancements

No major clinical trials for alternative indications are actively progressing as of 2023. Future investment may hinge on regulatory approvals and new safety/efficacy data.

Financial Risks and Opportunities

Risks:

• Patent expiry risking generic entry
• Regulatory challenges in expanding indications
• Competition from emerging non-hormonal therapies

Opportunities:

• Greater market penetration in Asia-Pacific
• Label expansion for additional menopausal symptoms
• Strategic partnerships or licensing deals for pipeline assets

Summary

Ospemifene's market is constrained by existing hormonal therapies but benefits from a niche for patients seeking non-estrogenic options. Its revenue trajectory depends on patent protections, competitive pressures, and regional adoption rates. Near-term growth prospects remain guarded but could improve through geographic expansion and label alterations.

---

Key Takeaways

• The global market for ospemifene was valued at USD 125 million in 2021, with potential growth to USD 175 million by 2025.
• Competition primarily comes from vaginal estrogen products; ospemifene’s non-estrogenic profile offers a differentiator.
• Patent expiry around 2028 poses significant revenue risks due to impending generic entries.
• Regional growth is driven by demographics, healthcare policies, and prescriber preferences.
• No significant pipeline developments are underway beyond its current indication, limiting future upside without label expansion.

---

FAQs

1. What factors could extend the market life of ospemifene?
Label expansions to include additional menopausal symptoms and geographic growth in emerging markets could prolong its revenue.

2. How does patent expiration affect ospemifene’s profitability?
Patent expiry typically invites generic competition, reducing prices and market share, which can significantly diminish revenues.

3. Are there safety concerns that limit ospemifene’s use?
Safety data are favorable, but concerns about thromboembolism and breast cancer risks associated with estrogen receptor modulators influence prescribing behaviors.

4. What is the expected timeline for generic versions?
Generic versions could enter the market around 2028, or sooner if patent challenges succeed.

5. Which strategic moves could enhance ospemifene’s market position?
Expanding indications, entering new regional markets, and securing partnerships for pipeline development are key strategies.

---

References

1. Grand View Research. Vaginal estrogen market size, 2021-2028.
2. FDA. Osphena approval details, 2013.
3. IQVIA. Pharmaceutical sales data, 2021-2022.
4. MarketWatch. Menopausal health market forecasts, 2022.
5. Regulations.gov. US patent information for ospemifene.